Job Scam Alert
Any emails received from hr@spauldingrehab.org or calls from (816) 263-2347 are fraudulent and not affiliated with Spaulding Rehabilitation or Mass General Brigham. Any emails or calls should be deleted and blocked.
More Information >
The EB-COP provides a systematic methodology for conducting more precise, evidence-based assessment of clinical outcome assessment measures (COAs) by evaluating performance within specific contexts of use (COUs) such as diagnosis, prognosis, or treatment response.
Authors & Design Team
Andrea N. Christoforou, PhD (Spaulding Rehabilitation)
Melissa J. Armstrong, MD, MSc (University of Florida)
Michael J. G. Bergin, PhD (Spaulding Rehabilitation)
Ann Robbins, PhD (Ann Robbins LLC)
Shannon A. Merillat, MLIS (American Academy of Neurology)
Patricia Erwin (Mayo Clinic)
Thomas S. D. Getchius (American Academy of Neurology, American Heart Association)
Michael McCrea, PhD (Medical College of Wisconsin)
Amy J. Markowitz, JD (University of California, San Francisco)
Geoffrey T. Manley, MD, PhD (University of California, San Francisco)
Predominantly designed to evaluate COAs for people with traumatic brain injury (TBI) but may be adapted for other populations.
Description
Among the more than 1,000 COAs currently used for TBI, few have been systematically evaluated to determine their performance within specific COU. As described by the U.S. Food and Drug Administration, the COU specifies the population of interest and the purpose for which the COA will be employed. COAs are commonly used for screening, diagnostic categorization, outcome prediction and establishing treatment effectiveness. Despite the pivotal role that outcome assessment plays in research, COA selection typically relies on expert consensus. There is currently no methodology designed to determine the appropriateness of a particular COA within a specific COU. To address this gap, we developed and pilot tested the Evidence-Based Clinical Outcome Assessment Platform (EB-COP) to efficiently and transparently evaluate the suitability of TBI COAs for specific purposes of use (PoUs). Development of the EB-COP was informed by the FDA’s Roadmap to Patient-Focused Outcome Measurement in Clinical Trials, the American Academy of Neurology’s (AAN’s) well-established Clinical Practice Guideline Process Manual, the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and other literature describing standards for measurement development.
The framework of the EB-COP is built around the six distinct PoUs shown below:
